NASDAQ
EVAX

Evaxion Biotech AS

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Evaxion Biotech AS Stock Price

Vitals

Today's Low:
$0.7504
Today's High:
$0.801
Open Price:
$0.8
52W Low:
$0.92
52W High:
$3.18
Prev. Close:
$0.781
Volume:
75048

Company Statistics

Market Cap.:
$40.45 million
Book Value:
0.344
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-50.78%
Return on Equity TTM:
-113.74%

Company Profile

Evaxion Biotech AS had its IPO on 2021-02-05 under the ticker symbol EVAX.

The company operates in the Healthcare sector and Biotechnology industry. Evaxion Biotech AS has a staff strength of 63 employees.

Stock update

Shares of Evaxion Biotech AS opened at $0.8 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.75 - $0.8, and closed at $0.79.

This is a +0.73% increase from the previous day's closing price.

A total volume of 75,048 shares were traded at the close of the day’s session.

In the last one week, shares of Evaxion Biotech AS have slipped by -3%.

Evaxion Biotech AS's Key Ratios

Evaxion Biotech AS has a market cap of $40.45 million, indicating a price to book ratio of 3.8052 and a price to sales ratio of 0.

In the last 12-months Evaxion Biotech AS’s revenue was $0 with a gross profit of $0 and an EBITDA of $-24907000. The EBITDA ratio measures Evaxion Biotech AS's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Evaxion Biotech AS’s operating margin was 0% while its return on assets stood at -50.78% with a return of equity of -113.74%.

In Q1, Evaxion Biotech AS’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Evaxion Biotech AS’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.93 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Evaxion Biotech AS’s profitability.

Evaxion Biotech AS stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.3219. Its price to sales ratio in the trailing 12-months stood at 0.

Evaxion Biotech AS stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$-64809000.00
Total Liabilities
$0
Operating Cash Flow
$0
Capital Expenditure
$440000
Dividend Payout Ratio
0%

Evaxion Biotech AS ended 2024 with $-64809000.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $-64809000.00 while shareholder equity stood at $-78722000.00.

Evaxion Biotech AS ended 2024 with $0 in deferred long-term liabilities, $0 in other current liabilities, in common stock, $-78722000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.24 million and cash and short-term investments were $10.24 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Evaxion Biotech AS’s total current assets stands at $10.24 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.

In 2024, Evaxion Biotech AS's operating cash flow was $0 while its capital expenditure stood at $440000.

Comparatively, Evaxion Biotech AS paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.79
52-Week High
$3.18
52-Week Low
$0.92
Analyst Target Price
$10.67

Evaxion Biotech AS stock is currently trading at $0.79 per share. It touched a 52-week high of $3.18 and a 52-week low of $3.18. Analysts tracking the stock have a 12-month average target price of $10.67.

Its 50-day moving average was $1.08 and 200-day moving average was $1.41 The short ratio stood at 2.92 indicating a short percent outstanding of 0%.

Around 4247.3% of the company’s stock are held by insiders while 40% are held by institutions.

Frequently Asked Questions About Evaxion Biotech AS

The stock symbol (also called stock or share ticker) of Evaxion Biotech AS is EVAX

The IPO of Evaxion Biotech AS took place on 2021-02-05

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
AIA Group Ltd (AAIGF)
$8.38
-0.14
-1.66%
$7.76
0.11
+1.44%
$82.83
-1.92
-2.27%
CBTX Inc (CBTX)
$33.56
-0.06
-0.18%
$2.85
0.05
+1.79%
$82.93
-1.49
-1.77%
$48
-2.43
-4.82%
$348.4
-15.35
-4.22%
$62.1
1.33
+2.19%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Address

Dr. Neergaards Vej, Horsholm, Denmark, 2970